Old Web
English
Sign In
Acemap
>
authorDetail
>
Maria Whelden
Maria Whelden
Alexion Pharmaceuticals
Pharmacodynamics
Medicine
Lymphocyte
Neutropenia
Regulatory T cell
2
Papers
53
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.
2019
Journal for ImmunoTherapy of Cancer
Daruka Mahadevan
Mark C. Lanasa
Charles M. Farber
Manjari Pandey
Maria Whelden
Susan J. Faas
Terrie L Ulery
Anjli Kukreja
Lan Li
Camille L. Bedrosian
Xiaoping Zhang
Leonard T. Heffner
Show All
Source
Cite
Save
Citations (36)
First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)
2010
Blood
Daruka Mahadevan
Mark C. Lanasa
Maria Whelden
Susan Faas
Terrie L Ulery
Anjli Kukreja
Lan Li
Camille L. Bedrosian
Leonard T. Heffner
Show All
Source
Cite
Save
Citations (17)
1